Compare ENVA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | ACAD |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 2011 | 2000 |
| Metric | ENVA | ACAD |
|---|---|---|
| Price | $169.41 | $22.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 22 |
| Target Price | ★ $185.71 | $30.55 |
| AVG Volume (30 Days) | 195.4K | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.05 | ★ 69.12 |
| EPS | ★ 3.46 | 2.30 |
| Revenue | ★ $3,151,653,000.00 | $726,437,000.00 |
| Revenue This Year | $149.64 | $18.80 |
| Revenue Next Year | $16.42 | $11.70 |
| P/E Ratio | $48.89 | ★ $9.80 |
| Revenue Growth | 18.58 | ★ 40.45 |
| 52 Week Low | $89.00 | $14.45 |
| 52 Week High | $176.68 | $28.35 |
| Indicator | ENVA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 66.76 | 54.22 |
| Support Level | $153.44 | $20.80 |
| Resistance Level | $176.68 | $22.97 |
| Average True Range (ATR) | 5.56 | 0.61 |
| MACD | 1.06 | 0.09 |
| Stochastic Oscillator | 78.25 | 86.89 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.